NFKB1 and cancer: GSK-3 inhibition downregulates the expression level of these NF-κB target genes [14], [38] and can also block the death receptor pathway [15], suggesting that GSK-3 inhibition might sensitize cancer cells to TRAIL treatment through multiple mechanisms.